BLLF1 g350 N-Terminal

SKU: orb1921729

Description

As the most abundant envelop glycoprotein of EBV, gp350 is encoded by the BLLF1 gene, heavily glycosylated and localizing to a variety of subcellular compartments of replicating cells. BLLF1 gp350 comprises an external, transmembrane, and internal domain. The interaction between EBV and the B lymphocyte surface is initially mediated by gp350 through binding to a B-cell surface receptor, CD21. The gp350 N-terminal region contains the B-cell binding domain, which can be recognized by EBV-neutralizing monoclonal antibody 72A1 to inhibits EBV binding and invasion of host cells. The N-terminal 9-amino-acid sequence of gp350, 21EDPGFFNVE29, which has significant homology to an 11-amino-acid sequence of C3dg, EDPGKQLYNVE, binds to purified CR2 and CR2 (+), but not to CR2 (-), B- and T-lymphoblastoid cell lines . Because of its essential properties, gp350 has been considered as a potential candidate for an EBV vaccine.

Research Area

,Epstein-Barr Virus (EBV)

Images & Validation

• Tested Applications: CLIA, IA, LF

Key Properties

• Source: HEK293
• MW: 52.25 kDa
• Purity: > 90% pure (SDS-PAGE).

Storage & Handling

• Storage: For long term storage, the product should be stored at -20°C or lower.
• Form/Appearance: Purified,Liquid
• Expiration Date: 6 months from date of receipt.
• Disclaimer: For research use only